### Editorsials

**The Histopathological Classification of ANCA-associated Glomerulonephritis Comes of Age**
A. Tanna, C.D. Pusey ........................................ 265

**Composite Measures of Impact and Activity in Psoriatic Arthritis: A Conceptual Framework**
W. Tillett .................................................. 268

### Review

**Quality of Care for SLE: Mind the Knowledge Gap**
V. Golder, E.F. Morand, A.Y. Hoi ...................... 271

### Psoriatic Arthritis

**The 12-item PsA Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting**
M. Di Carlo, A. Becciolini, V. Lato, C. Crotti, E.G. Favalli, F. Salaffi ........................................ 279

**The Risk of Developing Diabetes Mellitus in Patients with PsA: A Cohort Study**
L. Eder, V. Chandran, R. Cook, D.D. Gladman ........ 286

### Sjögren Syndrome

**Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome**

### Vasculitis

**Giant Cell Arteritis–related Stroke: A Retrospective Multicenter Case-control Study**
H. de Boysson, E. Liozon, D. Larivièere, et al ........ 297

**Histopathological Classification and Renal Outcome in Patients with ANCA-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis**
Y.X. Chen, J. Xu, X.X. Pan, et al .......................... 304

**Incidence of Malignancy Prior to ANCA–associated Vasculitis Compared to the General Population**
E.E. van Daalen, C. Rahmatullla, R. Wolterbeek, J.A. Brujin, I.M. Bajema .............................. 314

### Myositis

**Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis**
S. Moghadam-Kia, C.V. Oddis, S. Sato, M. Kuwana, R. Aggarwal .......................... 319

### Pediatric Rheumatology

**Clinical Orofacial Examination in JIA: International Consensus-based Recommendations for Monitoring Patients in Clinical Practice and Research Studies**

**Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study**
F.A. Aeschlimann, F. Angst, K.D. Hofer, et al .......................... 334

**The Juvenile PsA Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes**

**Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance**
D.B. Horton, K.B. Onel, T. Beukelman, S. Ringold ........ 352

**Sleep Disturbances and Neurobehavioral Performance in JIA**

### Gout

**Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study**
Z.L. Vincent, G. Gamble, M. House, et al ............... 368

**The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout**
A.S. Steinberg, B.D. Vince, Y.J. Choi, R.L. Martin, C.A. McWherter, P.F. Boudes .......................... 374

---

© Free online via JRheum Full Release option

Contents continued on page xvi
Sex-specific Relationship of Serum Uric Acid with All-cause Mortality in Adults with Normal Kidney Function: An Observational Study

Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review
A. Shiozawa, S.M. Szabo, A. Bolzani, A. Cheung, H.K. Choi ............................................. 388

Correspondence
Association of Colchicine Price and Emergency Department Visits for Gout? M.E. Mullins .............. 397
Reply S. Jinno ........................................... 397

Letter
Increased Incidence of GI Side Effects in Patients Taking HCQ: A Brand-related Issue?
A. Srinivasa, S. Tosounidou, C. Gordon .................. 398

Meetings in Rheumatology ................................. x